Business Wire

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

Share

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Vivet’s two proprietary AAV gene therapy programs for progressive familial intrahepatic cholestasis (PFIC), subtypes 3 and 2. The two programs, VTX-803 and VTX-802, are currently being evaluated in preclinical studies by Vivet, a privately-held gene therapy biotechnology company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005354/en/

Under the terms of the agreement, Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the programs. Until that time, Mirum will provide funding to support the continued research and development costs associated with the two gene therapy programs.

“This gene therapy collaboration will work to address the root cause of PFIC3 and PFIC2 and provide an option for patients who do not respond to ASBT inhibition,” said Chris Peetz, president and chief executive officer at Mirum. “We are encouraged by the expertise and dedication of the Vivet team to develop next-generation gene therapies that have the potential to transform the lives of patients and their families. There are clear synergies in our combined missions to help the people who need it the most.”

“Mirum’s dedication to the treatment of cholestatic liver diseases and those rare diseases for which there are limited medications make them a great partner to potentially develop and bring to market VTX-803 and VTX-802,” said Jean-Philippe Combal, chief executive officer and co-founder of Vivet. “Their leadership in rare liver disease and in particular PFIC, is important as they not only understand the urgent need for patients but also that today’s treatment options will never be enough. Gene therapy is a transformative approach, potentially benefiting more patients.”

VTX-803 and VTX-802 are two proprietary AAV gene therapy programs of Vivet currently being evaluated in preclinical studies for progressive familial intrahepatic cholestasis (PFIC), subtypes 3 and 2. It is thought that successful correction by gene therapy of the defective MDR3 transporter and bile salt export pump (BSEP) functions for PFIC3 and PFIC2, respectively, may ultimately provide a cure for patients living with these rare liver diseases. Such an approach carries the potential to overcome the main limitations of current standard of care for PFIC3 and PFIC2. It may provide long-lasting benefits by restoring physiological bile secretion and preventing severe hepatic complications of the diseases and outweighing its related significant costs.

Vivet has received Orphan Drug Designation for VTX-803 by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, preclinical proof-of-concept studies highlighting VTX-803 were published in Nature Communications in 2019. The data demonstrated sustained and significant reversal of PFIC3 disease biomarkers in a model of PFIC3.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency. Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics, following preclinical evaluation and IND/CTA-enabling studies.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

About Vivet Therapeutics

Vivet Therapeutics is a clinical stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

Vivet is building a diversified gene therapy pipeline based on novel recombinant adeno-associated virus (rAAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain.

Vivet’s lead program, VTX-801, currently under IND clinical development with the GATEWAY clinical trial, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC). This rare genetic disorder is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels causing severe hepatic damages, neurologic symptoms and potentially death.

Vivet’s second gene therapy product, VTX-803 for PFIC3, received US and European Orphan Drug Designation in May 2020.

Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer Inc., Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partners.

Please visit us on www.vivet-therapeutics.com and follow us on Twitter at @Vivet_tx and LinkedIn.

About PFIC

Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic disorder that causes progressive liver disease typically leading to liver failure. In people with PFIC, liver cells are less able to secrete bile. The resulting buildup of bile causes liver disease in affected individuals. Signs and symptoms of PFIC typically begin in infancy. Patients experience severe itching, jaundice, failure to grow at the expected rate (failure to thrive), and an increasing inability of the liver to function (liver failure). The disease is estimated to affect one in every 50,000 to 100,000 births in the United States and Europe. Six types of PFIC have been genetically identified, all of which are similarly characterized by impaired bile flow and progressive liver disease The PFIC2 patient population accounts for approximately 60% of the PFIC patient population. PFIC2 is caused by a mutation in the ABCB11 gene, which normally encodes a bile salt export pump protein that moves bile acids out of the liver.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the option and license agreement between Mirum and Vivet and the potential development of VTX-802 and VTX-803. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” ”may,” “anticipates,” “expects,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mirum Contacts:
Media:
Erin Murphy
media@mirumpharma.com

Investors:
Ian Clements, Ph.D.
ir@mirumpharma.com

Vivet Therapeutics Contacts:
Media Relations:
Thomas Daniel
info@vivet-therapeutics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Halliburton and TGS Collaborate to Advance Seismic Reservoir Monitoring18.5.2021 14:00:00 EEST | Press release

Halliburton Company (NYSE: HAL) and TGS-NOPEC Geophysical ASA (OSLO:TGS) today announced a collaboration to bring advanced seismic imaging to fiber optic sensing. The alliance will provide operators with advanced insight to determine their reservoir potential for oil and gas production or carbon storage. The Halliburton FiberVSP™ and Odassea™ distributed acoustic sensing solutions will now incorporate TGS’s seismic imaging workflows that process the entire seismic wavefield to generate high-resolution reservoir images. “We are excited to transform vertical seismic profiling to a full-field, digital, and intervention-less surveillance solution,” said Trey Clark, vice president of Wireline and Perforating. “Through our collaboration with TGS, we can now enable real-time monitoring of production across an entire field, allowing our customers to make better decisions and increase ultimate recovery.” “This solution enables enhanced reservoir understanding for our customers with a lower tota

Hewlett Packard Enterprise Launches Gaia-X Solutions to Accelerate Data Value Creation18.5.2021 14:00:00 EEST | Press release

Hewlett Packard Enterprise (NYSE: HPE) today announced solutions to help organizations advance data monetization by tapping into Gaia-X, an emerging federated data infrastructure supported by more than 300 organizations in Europe and globally. The HPE Solution Framework for Gaia-X was designed for companies, service providers and public organizations that want to get ready to participate in Gaia-X. It supports virtually all capabilities that are required to both provide and consume data and services in a decentralized, federated environment. As a result, organizations can advance their ability to create value from data, tap into huge distributed data pools, and strengthen their sovereignty over their data-driven business model. The framework is based on a reference architecture, leveraging key components of HPE’s software portfolio, third-party software, and the Cloud28+ business platform, a marketplace for the monetization of data and services. Individual solution components and entir

SoftServe Achieves AWS Machine Learning Competency18.5.2021 14:00:00 EEST | Press release

SoftServe, a leading digital authority and consulting company and an Amazon Web Services (AWS) Premier Consulting Partner, has achieved the AWS Machine Learning Competency. AWS Machine Learning Competency Partners have demonstrated expertise in delivering machine learning (ML) solutions on the AWS Cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005007/en/ “SoftServe has proven expertise in helping organizations solve their most pressing AI challenges including data engineering, machine learning, and production deployment for inference at scale,” said Todd Lenox, VP, Global Alliances and Partnerships at SoftServe. “The AWS Machine Learning Competency designation shows we are an AWS partner that has the services and technologies which create intelligent solutions by enabling data science workflows and enhancing applications with machine intelligence.” Achieving the AWS Machine Learning Competency differentiates Sof

Q3, FY 2021 Results: Mytheresa Reports Exceptional Net Sales Growth of 47.5% in Q3, FY 2021 Benefiting From the Accelerated Shift in Consumer Behavior Towards Digital and Increases Full Year Guidance18.5.2021 13:00:00 EEST | Press release

MYT Netherlands Parent B.V. (NYSE: MYTE) (“Mytheresa” or the “Company”), the parent company of Mytheresa Group GmbH, today announced financial results for its third quarter of FY 2021 ended March 31, 2021. The luxury online fashion business continued to benefit from the shift in consumer shopping behavior towards digital offerings, which shaped the strong results of the third quarter. Even taking into account the lower comparables of Q3 in FY2020 the accelerated growth is evidenced by the two-year growth rate of 66% versus the two-year growth rate of 60% for the second quarter of FY 2021. Michael Kliger, Chief Executive Officer of Mytheresa, said: “In the third quarter, our company was even able to accelerate our growth. This was largely driven by the continuous shift of consumer behavior towards digital and multi-brand offerings. We had a new record in first-time buyers in the quarter and our recently acquired customer cohorts show higher re-purchase rates than before. Additionally, w

Samsung Unveils New Power Management Solutions for DDR5 Modules18.5.2021 11:27:00 EEST | Press release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced the industry’s first integrated power management ICs (PMICs) — S2FPD01, S2FPD02 and S2FPC01, for the fifth-generation double data rate (DDR5) dual in-line memory module (DIMM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005479/en/ Samsung Unveils New Power Management Solutions for DDR5 Modules (Photo: Business Wire) One major design improvement to the newest generation DRAM solution involves integrating the PMIC into the memory module — previous generations placed the PMIC on the motherboard — offering increased compatibility and signal integrity, and providing a more reliable and sustained performance. For improved performance efficiency and load-transient responses, Samsung’s new PMICs for DDR5 modules have been equipped with a high-efficiency hybrid gate driver and a proprietary control design (asynchronous-based

The Council of the Hong Kong Laureate Forum Announced Deferment of Its Inaugural Hong Kong Laureate Forum to November 202218.5.2021 11:01:00 EEST | Press release

Given the prevailing situation of the COVID-19 pandemic, the progress of global and local vaccinations, as well as the global position on safe travel, the Board of the Council of the Hong Kong Laureate Forum Limited (the HKLF) has decided after careful consideration that the inaugural Hong Kong Laureate Forum (the Forum), originally scheduled to be held on 15-20 November 2021, would be deferred for one year to November 2022. Importance of going face-to-face The Board of the HKLF came to the view that the Forum should ideally be conducted in face-to-face mode given that the main aim of the Forum is to inspire young scientists by providing a platform of direct exchange amongst participating Shaw Laureates and young scientists. However, with the current situation of the pandemic, it is uncertain that safe and unrestricted international travel could be resumed in time for in-person meeting. Professor Timothy W. TONG, BBS, JP, Chairman of the HKLF, is confident about delivering a successful

Virtuozzo Reveals New Hybrid Cloud Solution, Designed Specifically for Managed and Cloud Service Providers18.5.2021 11:00:00 EEST | Press release

Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, has announced the availability of its newest product, Virtuozzo Hybrid Cloud. The solution enables Managed Service Providers (MSPs) and Cloud Service Providers (CSP) to design, build and sell modern cloud services to customers quickly and more cost-effectively than traditional hyperscalers. The cloud infrastructure market continues to experience strong growth as businesses become increasingly more dependent on cloud-based resources. This evolution presents an opportunity for service providers to carve out an alternative to the often complex and expensive traditional cloud providers. According to Liam Eagle, Research Director, 451 Research, a part of S&P Global Market Intelligence, “As the breadth of organizations seeking cloud solutions continues to grow, a gap in the skills necessary to navigate the complexities of the most advanced cloud platforms is a common limitation. This presents

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom